Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Zacks
More News
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Zacks
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Zacks.com featured highlights include Bassett Furniture, Aveanna Healthcare and Integra LifeSciences
Bassett Furniture, Aveanna Healthcare and Integra LifeSciences are highlighted as potential breakout stocks using support and resistance levels ahead of August.
Zacks
3 Stocks Showing Breakout Potential Ahead of August
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.
Zacks
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
Integra LifeSciences (IART) Q2 Earnings Top Estimates
Integra (IART) delivered earnings and revenue surprises of +16.67% and -0.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Reasons to Retain Align Technology Stock in Your Portfolio for Now
ALGN's global expansion and iTero innovations support growth, but can they offset currency headwinds and macro pressures?
Zacks
Kaskela Law Firm Announces Investigation of Integra LifeSciences (IART) and Encourages Long-Term IART Shareholders with Investment Losses to Contact the Firm
Investor litigation firm Kaskela Law announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (Integra) on behalf of the companys long-term investors. Click here for additional information: https://kaskelalaw.com/cases/integra-lifesciences/ Recently a securities fraud...